carnitine has been researched along with Vascular Diseases in 13 studies
Vascular Diseases: Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We recently reported that endothelial carnitine palmitoyltransferase 1a (Cpt1a) is reduced by hyperoxia, and that endothelial cell-specific Cpt1a knockout mice are more susceptible to developing hyperoxia-induced injury than wild type mice." | 8.12 | Upregulating carnitine palmitoyltransferase 1 attenuates hyperoxia-induced endothelial cell dysfunction and persistent lung injury. ( Chang, J; Chang, JL; Dennery, PA; Gong, J; Peterson, AL; Rizal, S; Yao, C; Yao, H, 2022) |
| "The article investigates the impact of complex tools fosinopril, hepadyf and ezetimibe for correction of functional state of the endothelium and changes in blood pressure in patients with nonalcoholic steatohepatitis, obesity and essential hypertension stage II." | 7.80 | [The use of complex tools ezetimibe, hepadyfu fosinopril and correction of blood pressure and endothelial dysfunction in patients with nonalcoholic steatohepatitis and essential hypertension stage II]. ( Drozd, VIu; Haĭdychuk, VS; Khukhlina, OS; Kosar, LIu; Mandryk, OIe, 2014) |
| " We recently reported that endothelial carnitine palmitoyltransferase 1a (Cpt1a) is reduced by hyperoxia, and that endothelial cell-specific Cpt1a knockout mice are more susceptible to developing hyperoxia-induced injury than wild type mice." | 4.12 | Upregulating carnitine palmitoyltransferase 1 attenuates hyperoxia-induced endothelial cell dysfunction and persistent lung injury. ( Chang, J; Chang, JL; Dennery, PA; Gong, J; Peterson, AL; Rizal, S; Yao, C; Yao, H, 2022) |
| "The article investigates the impact of complex tools fosinopril, hepadyf and ezetimibe for correction of functional state of the endothelium and changes in blood pressure in patients with nonalcoholic steatohepatitis, obesity and essential hypertension stage II." | 3.80 | [The use of complex tools ezetimibe, hepadyfu fosinopril and correction of blood pressure and endothelial dysfunction in patients with nonalcoholic steatohepatitis and essential hypertension stage II]. ( Drozd, VIu; Haĭdychuk, VS; Khukhlina, OS; Kosar, LIu; Mandryk, OIe, 2014) |
| "Carnitine is an important cofactor for normal cellular metabolism." | 2.39 | Carnitine metabolism during exercise. ( Brass, EP; Hiatt, WR, 1994) |
| "Carnitine is an essential cofactor for mitochondrial import and oxidation of fatty acids." | 1.56 | Carnitine Profile Changes in Pediatric Hematopoietic Stem Cell Transplant: New Role for Carnitine? ( Fenton, TR; Fung, E; Law, SF; Lewis, V; Snyder, FF, 2020) |
| "The authors have evaluated the efficacy of chronic administration of propionyl l-carnitine versus Buflomedil chlorhydrate in patients affected by vasculopathies." | 1.28 | Rheological activity of propionyl L-carnitine. ( Flore, R; Nolfe, G; Pola, P; Tondi, P, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 6 (46.15) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, JL | 1 |
| Gong, J | 1 |
| Rizal, S | 1 |
| Peterson, AL | 1 |
| Chang, J | 1 |
| Yao, C | 1 |
| Dennery, PA | 1 |
| Yao, H | 1 |
| Law, SF | 1 |
| Fenton, TR | 1 |
| Snyder, FF | 1 |
| Fung, E | 1 |
| Lewis, V | 1 |
| Mohammadi, M | 1 |
| Hajhossein Talasaz, A | 1 |
| Alidoosti, M | 1 |
| Khukhlina, OS | 1 |
| Mandryk, OIe | 1 |
| Drozd, VIu | 1 |
| Haĭdychuk, VS | 1 |
| Kosar, LIu | 1 |
| Lever, M | 1 |
| George, PM | 1 |
| Dellow, WJ | 1 |
| Scott, RS | 1 |
| Chambers, ST | 1 |
| Takenaka, T | 1 |
| Kanno, Y | 1 |
| Ohno, Y | 1 |
| Suzuki, H | 1 |
| Brass, EP | 3 |
| Hiatt, WR | 3 |
| Bertelli, A | 1 |
| Giovannini, L | 1 |
| Galmozzi, G | 1 |
| Bertelli, AA | 1 |
| Regensteiner, JG | 1 |
| Wolfel, EE | 1 |
| Carry, MR | 1 |
| Pola, P | 3 |
| De Martini, D | 1 |
| Gerardino, L | 1 |
| De Rossi, S | 1 |
| Tondi, P | 3 |
| Flore, R | 2 |
| Serricchio, M | 1 |
| Nolfe, G | 1 |
| Nawaz, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Use of Acetyl L-Carnitine in Patients With Covid-19 Pneumonia[NCT04623619] | 100 participants (Anticipated) | Interventional | 2020-12-15 | Not yet recruiting | |||
| Evaluation of Cilostazol in Combination With L-Carnitine in Subjects With Intermittent Claudication[NCT00822172] | Phase 4 | 164 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. The time during the conduct of the exercise treadmill test at which the subject first reported claudication symptoms is referred to as the claudication onset time (COT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 1.065 |
| Cilostazol + Placebo | 0.896 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. The time during the conduct of the exercise treadmill test at which the subject first reported claudication symptoms is referred to as the claudication onset time (COT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 90
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 1.001 |
| Cilostazol + Placebo | 0.815 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 0.241 |
| Cilostazol + Placebo | 0.134 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 0.267 |
| Cilostazol + Placebo | 0.145 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 90
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 0.166 |
| Cilostazol + Placebo | 0.139 |
Subjects completed the Walking Impairment Questionnaire (WIQ) whereby they were asked about their maximal walking distance before having to rest as a result of claudication symptoms associated with their peripheral artery disease (PAD). The WIQ was administered at the Baseline, Day 90, and Day 180 visits. On the WIQ subjects were asked a series of questions related to their degree of physical difficulty that best described how hard it was for the subject to walk on level ground without stopping to rest. The questions began by asking the degree of difficulty walking around indoors, then 50 feet, 150 feet, 300 feet, 600 feet, 900 feet, and lastly 1500 feet. The responses range from None (best outcome) to Slight, then Some, then Much, then lastly Unable (worst outcome). The walking distance score was calculated from the 7 questions in the section by way of a weighted sum. A score of 100 indicated no walking impairment. A score of 0 corresponded to the highest degree of walking impairment (NCT00822172)
Timeframe: Baseline, Day 180
| Intervention | score on a scale (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 13.20 |
| Cilostazol + Placebo | 6.57 |
Subjects completed the Walking Impairment Questionnaire (WIQ) whereby they were asked about their maximal walking distance before having to rest as a result of claudication symptoms associated with their peripheral artery disease (PAD). The WIQ was administered at the Baseline, Day 90, and Day 180 visits. On the WIQ subjects were asked a series of questions related to their degree of physical difficulty that best described how hard it was for the subject to walk on level ground without stopping to rest. The questions began by asking the degree of difficulty walking around indoors, then 50 feet, 150 feet, 300 feet, 600 feet, 900 feet, and lastly 1500 feet. The responses range from None (best outcome) to Slight, then Some, then Much, then lastly Unable (worst outcome). The walking distance score was calculated from the 7 questions in the section by way of a weighted sum. A score of 100 indicated no walking impairment. A score of 0 corresponded to the highest degree of walking impairment (NCT00822172)
Timeframe: Baseline, Day 90
| Intervention | score on a scale (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 12.98 |
| Cilostazol + Placebo | 10.01 |
2 reviews available for carnitine and Vascular Diseases
| Article | Year |
|---|---|
Preventive effect of l-carnitine and its derivatives on endothelial dysfunction and platelet aggregation.
Topics: Acetylcarnitine; Animals; Antioxidants; Carnitine; Cell Adhesion; Cell Adhesion Molecules; Clinical | 2016 |
Carnitine metabolism during exercise.
Topics: Acetyl Coenzyme A; Acetylcarnitine; Adenosine Triphosphate; Carnitine; Exercise; Humans; Lactates; M | 1994 |
1 trial available for carnitine and Vascular Diseases
| Article | Year |
|---|---|
Effect of exercise training on skeletal muscle histology and metabolism in peripheral arterial disease.
Topics: Aged; Carnitine; Exercise; Hemodynamics; Humans; Intermittent Claudication; Muscle Fibers, Skeletal; | 1996 |
10 other studies available for carnitine and Vascular Diseases
| Article | Year |
|---|---|
Upregulating carnitine palmitoyltransferase 1 attenuates hyperoxia-induced endothelial cell dysfunction and persistent lung injury.
Topics: Animals; Animals, Newborn; Bronchopulmonary Dysplasia; Carnitine; Carnitine O-Palmitoyltransferase; | 2022 |
Carnitine Profile Changes in Pediatric Hematopoietic Stem Cell Transplant: New Role for Carnitine?
Topics: Adolescent; Biomarkers; Carnitine; Child; Child, Preschool; Cohort Studies; Female; Follow-Up Studie | 2020 |
[The use of complex tools ezetimibe, hepadyfu fosinopril and correction of blood pressure and endothelial dysfunction in patients with nonalcoholic steatohepatitis and essential hypertension stage II].
Topics: Adenine; Anticholesteremic Agents; Azetidines; Carnitine; Drug Combinations; Endothelium, Vascular; | 2014 |
Homocysteine, glycine betaine, and N,N-dimethylglycine in patients attending a lipid clinic.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Betaine; Carnitine; Creatinine; Female; Homocysteine; Hu | 2005 |
Key role of insulin resistance in vascular injury among hemodialysis patients.
Topics: Aged; Blood Pressure; Carnitine; Cyclohexanes; Diabetic Nephropathies; Female; Homeostasis; Humans; | 2007 |
Protective role of propionyl carnitine in vascular disorders experimentally induced by endothelin (ET-1) serotonin and K-carrageenin.
Topics: Animals; Cardiovascular Agents; Carnitine; Carrageenan; Endothelins; Male; Rats; Rats, Wistar; Regio | 1993 |
The action of propionyl-L-carnitine on the vasal endothelium: increased t-PA synthesis and a decrease in the activity of PAI-1. A preliminary study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aging; Cardiotonic Agents; Carnitine; Endothelium, Vascu | 1992 |
New carnitine derivatives for the therapy of cutaneous ulcers in vasculopathics.
Topics: Aged; Aged, 80 and over; Carnitine; Female; Humans; Leg Ulcer; Male; Middle Aged; Skin Ulcer; Vascul | 1991 |
Rheological activity of propionyl L-carnitine.
Topics: Adenosine Diphosphate; Blood Viscosity; Carnitine; Humans; Pyrrolidines; Vascular Diseases | 1991 |
Carnitine metabolism during exercise in patients with peripheral vascular disease.
Topics: Blood Pressure; Carnitine; Female; Heart Rate; Humans; Male; Middle Aged; Oxygen Consumption; Physic | 1987 |